Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16712
Title: Statistical analysis plan for the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial
Austin Authors: Billot, Laurent;Venkatesh, Balasubramanian;Myburgh, John;Finfer, Simon;Cohen, Jeremy;Webb, Steve;McArthur, Colin;Joyce, Christopher;Bellomo, Rinaldo ;Rhodes, Andrew;Perner, Anders;Arabi, Yaseen;Rajbhandari, Dorrilyn;Glass, Parisa;Thompson, Kelly;Correa, Maryam;Harward, Meg
Affiliation: The George Institute for Global Health, Sydney, NSW, Australia
Sydney Medical School, University of Sydney, Sydney, NSW, Australia
Royal North Shore Hospital, Sydney, NSW, Australia
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Royal Perth Hospital, Perth, Western Australia, Australia
Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand
Department of Intensive Care, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Austin Health, Heidelberg, Victoria, Australia
St George's Hospital, London, UK
Rigshospitalet, Copenhagen, Denmark
King Abdulaziz Medical City, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
Issue Date: Jun-2017
Publication information: Critical Care and Resuscitation 2017; 19(2): 183-191
Abstract: BACKGROUND: The Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial, a 3800-patient, multicentre, randomised controlled trial, will be the largest study to date of corticosteroid therapy in patients with septic shock. OBJECTIVE: To describe a statistical analysis plan (SAP) and make it public before completion of patient recruitment and data collection. The SAP will be adhered to for the final data analysis of this trial, to avoid analysis bias arising from knowledge of study findings. METHODS: The SAP was designed by the chief investigators and statisticians and approved by the ADRENAL management committee. All authors were blind to treatment allocation and to the unblinded data produced during two interim analyses conducted by the Data Safety and Monitoring Committee. The data shells were produced from a previously published protocol. Statistical analyses are described in broad detail. Trial outcomes were selected and categorised into primary, secondary and tertiary outcomes, and appropriate statistical comparisons between groups are planned and described in a way that is transparent, available to the public, verifiable and determined before completion of data collection. RESULTS: We developed a standard SAP for the ADRENAL trial, and have produced a trial profile outline and list of mock tables. We describe analyses of baseline characteristics, processes of care, measures of efficacy and outcomes. Six pre-specified subgroups were defined, and statistical comparisons between groups in these subgroups are described. CONCLUSION: We have developed an SAP for the ADRENAL trial. This plan accords with high-quality standards of internal validity to minimise analysis bias.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16712
ORCID: 0000-0002-1650-8939
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28651515
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.